Alagille Syndrome

Alagille syndrome is a rare genetic condition that affects many body systems. The most common problem is in the liver, where there are too few small bile ducts inside the liver. This is called paucity of intrahepatic bile ducts. Because bile cannot flow out well, bile builds up. This causes cholestasis, which leads to jaundice, very strong itching (pruritus), fatty stools, poor growth, xanthomas (fat deposits on skin), and lack of fat-soluble vitamins (A, D, E, K). ALGS often also affects the heart (especially the pulmonary arteries), the skeleton (butterfly-shaped vertebrae), the eyes (posterior embryotoxon), the kidneys, the blood vessels (brain and body), and gives characteristic facial features (broad forehead, deep-set eyes, pointed chin). The diagnosis can be made by clinical criteria or by finding a pathogenic variant in the JAG1 or NOTCH2 gene. Inheritance is autosomal dominant with variable expressivity (even within the same family). Management is multidisciplinary and includes nutrition, bile-flow medicines, anti-itch strategies, fat-soluble vitamins, new bile-acid blocker medicines, and sometimes surgery or liver transplant. Regular liver cancer surveillance (ultrasound and alpha-fetoprotein every 6 months) is recommended in many patients. NCBI

Alagille syndrome is a genetic condition that affects how many organs develop and work, especially the liver and the heart. In most babies and children with Alagille syndrome, the tiny tubes that carry bile out of the liver (bile ducts) are too few or do not form normally. This is called bile duct paucity. When bile cannot flow out well, it builds up in the liver. This causes cholestasis (reduced bile flow), which leads to yellow skin and eyes (jaundice), itching, pale stools, dark urine, poor absorption of vitamins, poor growth, and sometimes liver damage.

Alagille syndrome does not only affect the liver. It can also affect the heart and blood vessels (most often pulmonary artery stenosis), the face (many children have a characteristic triangular face with a broad forehead, deep-set eyes, and a pointed chin), the eyes (a ring at the edge of the cornea called posterior embryotoxon), the spine (butterfly-shaped vertebrae on X-ray), the kidneys, and sometimes the brain’s blood vessels.

It is usually caused by a change (pathogenic variant) in one of two genes that are part of the Notch signaling pathway, a key pathway that guides organ development in the embryo. The condition is autosomal dominant, which means one changed copy of the gene is enough to cause the condition. The change can be inherited from a parent or can be de novo (new in the child). The severity is very variable: some people have mild disease and grow into adulthood with few problems, while others have serious liver or heart issues that need advanced care.

Alagille syndrome is not caused by something the parents did during pregnancy. It is a genetic developmental condition present from birth, although some features appear later as the child grows.

---

Other names

• ALGS (short form)

• Alagille–Watson syndrome

• Syndromic bile duct paucity

• Arteriohepatic dysplasia (older name, less used now)

• ALGS type 1 (JAG1-related) / ALGS type 2 (NOTCH2-related)

---

Types

There are two main genetic types and a few practical “clinical patterns.” Doctors may describe them in these ways:

1. ALGS type 1 (JAG1-related)
   This is the most common type (about 9 out of 10 cases). A pathogenic variant in the JAG1 gene on chromosome 20 disrupts signaling needed to form bile ducts, heart vessels, and other structures.

2. ALGS type 2 (NOTCH2-related)
   Less common. A pathogenic variant in NOTCH2 (the receptor in the same pathway) can cause similar features. Some patients have milder liver disease but may have more kidney involvement.

3. Liver-predominant pattern
   The liver signs (cholestasis, jaundice, itching, fat-soluble vitamin deficiency) are the main problem. Heart or kidney features may be mild or absent.

4. Heart-predominant pattern
   The heart or pulmonary arteries are the main issue (for example, pulmonary stenosis). Liver signs may be mild.

5. Multisystem pattern
   Clear involvement of liver, heart, face, eyes, skeleton, and sometimes kidneys and blood vessels.

Remember: these “patterns” are not strict subtypes. They just help describe how the condition shows up in a particular person.

---

Causes

Alagille syndrome is genetic. Below are 20 key cause-related points that explain what leads to the condition and why organs are affected:

1. JAG1 pathogenic variants (most common)
   A harmful change in the JAG1 gene reduces the amount or function of the JAG1 protein, which is a ligand in the Notch pathway. This disrupts organ development.

2. NOTCH2 pathogenic variants (less common)
   A harmful change in NOTCH2, the receptor partner for JAG1, also impairs the same pathway.

3. Autosomal dominant inheritance
   One changed copy of JAG1 or NOTCH2 is enough to cause disease. An affected parent has a 50% chance of passing the variant to a child.

4. De novo variants
   The gene change can be new in the child, even if both parents are unaffected. This explains many cases without family history.

5. Haploinsufficiency
   Often, having only one working copy of JAG1 is not enough for normal development. This “half dose” is called haploinsufficiency.

6. Loss-of-function variant types
   Nonsense, frameshift, and splice-site variants or whole-gene deletions often remove JAG1 function and cause disease.

7. Missense variants
   A single amino acid change can disturb how JAG1 or NOTCH2 folds or binds, lowering signaling strength.

8. Large microdeletions on chromosome 20p12
   Deletions that include JAG1 remove the gene entirely, producing typical Alagille features.

9. Mosaicism
   In a small number of families, a parent may carry the variant in some cells but not others (mosaicism), which can explain recurrence in siblings even if the parent seems unaffected.

10. Variable expressivity
    The same variant can look very different in different people (even in the same family). Modifying genes and environment may affect severity.

11. Reduced penetrance
    Some people with a pathogenic variant show mild or almost no signs, making family history hard to recognize.

12. Disrupted bile duct development
    Notch signaling guides bile duct formation. When it is weak, there are too few bile ducts, causing cholestasis.

13. Abnormal vascular development
    Notch also shapes arteries. Disruption can cause pulmonary artery stenosis and other vessel abnormalities.

14. Cardiac outflow tract effects
    The same pathway helps form the heart’s outflow structures, explaining murmurs and congenital heart disease.

15. Skeletal segmentation effects
    Notch participates in forming the vertebrae, explaining butterfly vertebrae on imaging.

16. Anterior eye segment differences
    Developmental changes lead to posterior embryotoxon, an eye finding seen by eye doctors.

17. Renal developmental differences
    The kidneys may be small, scarred, or have vessel issues, sometimes leading to high blood pressure.

18. Brain vessel differences
    Rarely, there are abnormalities in the brain’s arteries, which can increase risk of bleeding or stroke.

19. Gene-environment interaction (severity only)
    While not a cause, nutrition, infections, and other health factors may influence severity or complications.

20. Unknown genetic factors (small minority)
    A few people meet clinical criteria but no JAG1/NOTCH2 variant is found with routine tests; more advanced or future testing may identify the cause.

---

Symptoms and signs

Symptoms vary a lot. Some children have mild disease; others have many symptoms. Here are common features in simple terms:

1. Jaundice
   Yellow eyes and skin due to bile building up. Often appears in infancy and can come and go.

2. Itching (pruritus)
   Bile salts in the blood irritate nerves in the skin. Itching can be severe, disturb sleep, and cause scratch marks.

3. Pale or clay-colored stools
   Little bile in the intestine makes stools light. Urine may be dark because more pigment leaves through the kidneys.

4. Poor growth / failure to thrive
   Trouble absorbing fat and fat-soluble vitamins (A, D, E, K) can slow weight gain and height.

5. Fat-soluble vitamin deficiencies

   • Vitamin A: night vision problems, dry eyes/skin

   • Vitamin D: weak bones, bone pain, fractures

   • Vitamin E: poor balance or weakness in severe cases

   • Vitamin K: easy bruising and bleeding

6. Xanthomas
   Firm, yellow skin bumps caused by very high cholesterol from cholestasis.

7. Abdominal swelling or discomfort
   The liver may be enlarged. Sometimes the spleen enlarges too.

8. Tiredness (fatigue)
   Chronic cholestasis, poor sleep from itching, and low vitamins all contribute to low energy.

9. Characteristic facial features
   Many children have a triangular face, broad forehead, deep-set eyes, straight nose, and pointed chin.

10. Heart murmur or shortness of breath
    Often due to pulmonary artery stenosis. Some have more complex heart disease.

11. Eye finding (posterior embryotoxon)
    Usually does not bother vision, but it helps doctors recognize the syndrome.

12. Back issues
    Butterfly vertebrae are seen on X-ray; sometimes mild back pain or posture issues occur.

13. High blood pressure
    Can occur if the kidneys or their arteries are affected.

14. Bleeding tendency
    With vitamin K deficiency or low clotting factors, nosebleeds or easy bruising may happen.

15. Headache or neurologic symptoms (rare)
    If there are brain vessel problems, severe headache, weakness, or stroke-like symptoms can occur—this is uncommon but serious.

---

Diagnostic tests

Doctors confirm Alagille syndrome using history, exam, lab tests, genetic testing, and imaging. The goal is to show a typical pattern across organ systems and, when possible, to identify the gene change.

A) Physical examination

1. Overall exam for jaundice, scratch marks, and growth
   The doctor looks for yellowing of the eyes/skin, scratch lines from itching, and measures weight and height to see if growth is delayed.

2. Facial features assessment
   The doctor notes the facial shape (broad forehead, pointed chin) that often supports the diagnosis.

3. Heart examination (auscultation)
   Listening for a murmur that suggests pulmonary artery stenosis or other congenital heart disease.

4. Abdominal examination
   Gentle palpation detects enlarged liver and sometimes an enlarged spleen, signs that bile flow is reduced or the liver is under stress.

B) Manual / bedside tests

5. Stool color card comparison
   The family compares the child’s stool color with a color card. Pale or clay-colored stools suggest cholestasis and deserve urgent evaluation.

6. Liver span percussion / bedside liver size check
   Simple tapping and feeling of the abdomen helps estimate liver size before imaging confirms it.

7. Growth chart plotting and nutrition screen
   Weight, length/height, and head circumference are plotted over time on standard charts to detect faltering growth and guide nutrition support.

C) Laboratory and pathology tests

8. Fractionated bilirubin (direct and total)
   Elevated direct (conjugated) bilirubin points to cholestasis.

9. Cholestatic enzymes (GGT and alkaline phosphatase)
   These are often high in bile duct problems.

10. Serum bile acids
    High levels reflect reduced bile flow and correlate with itching.

11. Comprehensive liver function tests
    ALT/AST (liver cell enzymes), albumin, and PT/INR (clotting) show liver health and synthetic function.

12. Lipid profile
    Cholesterol and triglycerides may be very high when bile does not reach the gut.

13. Fat-soluble vitamin levels (A, D, E, K)
    Helps target vitamin replacement and prevent complications (vision issues, fractures, bleeding).

14. Genetic testing (JAG1 and NOTCH2)
    A blood test looks for pathogenic variants. Finding a JAG1 or NOTCH2 variant strongly supports the diagnosis and helps with family counseling.

15. Liver biopsy (histology)
    A small tissue sample shows bile duct paucity and other features. Biopsy is not always needed if genetic testing and clinical features are clear, but it can help when the diagnosis is uncertain.

D) Electrodiagnostic tests

16. Electrocardiogram (ECG)
    Records heart rhythm and strain patterns that can accompany congenital heart disease.

17. Brainstem auditory evoked response (BAER) in infants (when indicated)
    Checks hearing pathways with tiny electrical responses. Used if there are concerns about hearing or neurologic involvement.

E) Imaging tests

18. Liver and abdominal ultrasound
    First-line imaging. It checks liver size and texture, the gallbladder, and blood flow in nearby vessels.

19. Echocardiogram (heart ultrasound)
    Key test to look for pulmonary artery stenosis and other heart defects common in Alagille syndrome.

20. MRCP (magnetic resonance cholangiopancreatography)
    A special MRI that shows the bile ducts without radiation. It helps assess the bile duct tree when needed and can reduce the need for invasive procedures.

Non-pharmacological treatments (therapies & others)

Each item includes description, purpose, and mechanism in simple terms.

1. Multidisciplinary care program.
   What: Regular follow-up with hepatology, cardiology, ophthalmology, nephrology, nutrition, and genetics.
   Why: ALGS is multi-system; coordinated care prevents misses.
   How it helps: Teams detect complications early and adjust care and nutrition on time. NCBI

2. High-calorie nutrition plan.
   What: Frequent meals, calorie-dense foods, MCT-enriched formulas if needed.
   Why: Cholestasis causes fat malabsorption and poor growth.
   How: Increases energy intake despite malabsorption. Orpha

3. Enteral feeding support (NG/PEG) when growth falters.
   What: Tube feeds to meet targets.
   Why: Bypass feeding struggles and ensure consistent calories.
   How: Guarantees delivery of energy and vitamins. NASPGHAN

4. Fat-soluble vitamin monitoring and education.
   What: Routine labs and teaching families how and when to give A, D, E, K.
   Why: Deficiency is common and harmful.
   How: Prevents rickets, vision and nerve issues, and bleeding. NASPGHAN

5. Skin care bundle for itch.
   What: Short, lukewarm baths; fragrance-free emollients; soft clothing; keep nails short.
   Why: Itch causes skin breaks and infection.
   How: Protects the skin barrier and reduces triggers. AASLD

6. Sleep hygiene strategies.
   What: Cool bedroom, cotton sheets, timed baths, distraction tools.
   Why: Night itch ruins sleep and growth.
   How: Lowers skin temperature and reduces scratching cycles. AASLD

7. Physical therapy & safe weight-bearing activity.
   What: Individual exercise plan.
   Why: Prevents weak bones and delays motor skills.
   How: Stimulates bone and muscle, improves balance and growth. NCBI

8. Fall and fracture prevention.
   What: Home safety review; proper shoes; vitamin optimization.
   Why: Osteopenia and fractures are more common.
   How: Reduces injury risk while bones strengthen. NCBI

9. Dental care program.
   What: Early dental visits and fluoride.
   Why: Fat-soluble vitamin deficits and malnutrition affect teeth.
   How: Prevents caries and enamel problems. NASPGHAN

10. Eye care and low-vision services if needed.
    What: Scheduled eye exams.
    Why: Ocular signs are common.
    How: Protects vision and function. NCBI

11. Cardiac surveillance and timely intervention.
    What: Echo follow-up for pulmonary artery stenosis or complex lesions.
    Why: Heart disease drives symptoms and outcomes.
    How: Plans catheter or surgical fixes when needed. NCBI

12. Vascular risk screening (brain and body).
    What: Blood pressure checks; imaging if symptoms suggest vascular anomalies.
    Why: Intracranial events can occur.
    How: Early detection saves lives. NCBI

13. Itch triggers avoidance.
    What: Avoid heat, wool, long hot baths.
    Why: Heat worsens itch.
    How: Reduces cutaneous stimulation. AASLD

14. Psychosocial support.
    What: Counseling, peer groups.
    Why: Chronic itch and hospital care stress families.
    How: Improves coping and adherence. NCBI

15. School and learning support.
    What: Educational plans and attention/executive function screening yearly.
    Why: Some children have attention or executive challenges.
    How: Keeps school progress on track. NCBI

16. Liver cancer surveillance.
    What: Ultrasound and AFP every 6 months.
    Why: HCC risk exists in ALGS (even with mild liver disease).
    How: Allows early detection and treatment. NCBI

17. Immunization optimization (including HAV and HBV).
    What: Follow national schedules, consider HAV/HBV if not immune.
    Why: Protect a vulnerable liver.
    How: Prevents severe infections. NCBI

18. Avoid contact sports when at bleeding risk or with splenomegaly.
    What: Choose safe activities.
    Why: Portal hypertension or coagulopathy raises bleeding risk.
    How: Prevents trauma and bleeding. NCBI

19. Medication safety education.
    What: Avoid unnecessary hepatotoxins (e.g., excess acetaminophen).
    Why: Stressed liver needs protection.
    How: Reduces drug-induced injury. NCBI

20. Genetic counseling & family planning options.
    What: Discuss recurrence risk (50%) and prenatal/preimplantation options.
    Why: Inheritance is autosomal dominant with variable severity.
    How: Informs reproductive decisions. NCBI

---

Drug treatments

Important: Doses below are typical pediatric ranges used by specialists; exact dosing must be individualized by the treating clinician based on weight, age, labs, and comorbidities.

1. Ursodeoxycholic acid (UDCA/ursodiol) — Choleretic
   Dose: 10–15 mg/kg/day divided 2–3 times.
   When: Daily long-term.
   Purpose: Improve bile flow and labs; may ease symptoms.
   How: Hydrophilic bile acid displaces toxic bile acids; improves bile secretion.
   Side effects: Diarrhea; rare liver enzymes rise. NASPGHAN

2. Cholestyramine — Bile-acid sequestrant
   Dose: Children often 240 mg/kg/day divided (or 4 g up to QID in older kids), taken 4 hours apart from other drugs.
   When: First-line for itch.
   Purpose: Reduce pruritus.
   How: Binds bile acids in gut so they are excreted.
   Side effects: Bloating, constipation, poor absorption of vitamins/drugs. MDPI+1

3. Colesevelam/Colestipol — Bile-acid binders (alternatives)
   Dose: Specialist guided; similar timing separation.
   Purpose/How: Same as cholestyramine; sometimes better tolerated.
   Side effects: GI upset, vitamin malabsorption. AASLD

4. Rifampin (rifampicin) — Enzyme inducer antipruritic
   Dose: 5–10 mg/kg/day (often divided BID).
   When: If bile-acid binders are not enough.
   Purpose: Reduce itch.
   How: Induces hepatic enzymes; lowers pruritogens (e.g., autotaxin/LPA).
   Side effects: Hepatotoxicity, drug interactions, orange fluids. PMC+1

5. Naltrexone — Opioid antagonist
   Dose: ~0.25–1 mg/kg/day (max typical 50 mg/day) under specialist care.
   Purpose: Reduce itch refractory to other agents.
   How: Counteracts endogenous opioids thought to mediate cholestatic itch.
   Side effects: Withdrawal-like symptoms, nausea, liver enzyme rise. PMC

6. Sertraline — SSRI adjunct for itch
   Dose: Pediatric dosing individualized (commonly low dose, titrate).
   Purpose: Add-on for refractory pruritus and mood benefit.
   How: Central modulation of itch perception.
   Side effects: GI upset, sleep changes; monitor. NASPGHAN

7. Hydroxyzine (or other sedating antihistamines)
   Dose: Symptom-based at bedtime.
   Purpose: Help sleep when itch is severe.
   How: Sedation; modest itch relief.
   Side effects: Drowsiness, dry mouth. PMC

8. Maralixibat (LIVMARLI®) — IBAT inhibitor
   Dose: Start 190 mcg/kg once daily for 1 week, then 380 mcg/kg once daily, 30 min before first meal.
   When: For cholestatic pruritus in ALGS (≥1 year old).
   Purpose: Reduce itch and serum bile acids; improve quality of life.
   How: Blocks ileal bile-acid reuptake, increasing fecal bile-acid loss.
   Side effects: GI symptoms, liver test changes, fat-soluble vitamin deficiency (monitor A, D, E, K). FDA Access Data

9. Odevixibat (BYLVAY®) — IBAT inhibitor
   Dose in ALGS (≥12 months): 120 mcg/kg once daily with morning meal (titrate for tolerance).
   Purpose/How: Like maralixibat—lowers bile acids and itch.
   Side effects: Diarrhea, abdominal pain; monitor LFTs and vitamins.
   Regulatory note: FDA-approved for ALGS cholestatic pruritus (2023). FDA Access Data+1

10. Vitamin A (retinol) supplementation — Fat-soluble vitamin
    Dose: Specialist-guided; often high-dose with monitoring (e.g., up to ~1000 IU/kg/day with max limits in cirrhosis contexts).
    Purpose: Prevent night blindness, immune issues.
    How: Replaces malabsorbed vitamin.
    Side effects: Toxicity if overdosed (bone, liver). AASLD

11. Vitamin D (cholecalciferol/calcitriol)
    Dose: Based on level; may require high doses in cholestasis to correct deficiency.
    Purpose: Prevent rickets and fractures.
    How: Restores calcium–bone metabolism.
    Side effects: Hypercalcemia if excessive; labs needed. AASLD+1

12. Vitamin E (as TPGS/tocophersolan)
    Dose: 15–25 IU/kg/day (often 20–25 IU/kg/day) in cholestasis.
    Purpose: Prevent neuropathy and hemolysis.
    How: Water-soluble form absorbs without bile.
    Side effects: Rare; monitor levels. Gastro Journal+2PMC+2

13. Vitamin K (phytonadione)
    Dose: Individualized (oral or parenteral) to normalize INR.
    Purpose: Prevent bleeding.
    How: Replaces malabsorbed vitamin K.
    Side effects: Rare anaphylactoid reactions with IV. NCBI

14. Diuretics for ascites (spironolactone ± furosemide)
    Dose: Weight-based; specialist protocol.
    Purpose: Control fluid if portal hypertension develops.
    How: Promotes salt and water excretion.
    Side effects: Electrolyte imbalance. NCBI

15. Propranolol (if esophageal varices present)
    Dose: Specialist-directed.
    Purpose: Reduce variceal bleed risk (with endoscopic therapy).
    How: Lowers portal venous inflow.
    Side effects: Bradycardia, hypotension. NCBI

16. Antibiotics for suspected cholangitis (e.g., ceftriaxone per local protocol)
    Purpose: Treat bacterial infection promptly.
    How: Eradicates pathogens during bile stasis.
    Side effects: Drug-specific. NCBI

17. Ezetimibe (select cases of severe xanthomas)
    Dose: Specialist off-label.
    Purpose: Lower LDL/xanthomas when disfiguring.
    How: Blocks intestinal cholesterol absorption.
    Side effects: GI upset; monitor LFTs. NCBI

18. Calcium & phosphate supplements
    Purpose: Support bone health with vitamin D.
    How: Corrects mineral deficits.
    Side effects: Constipation; monitor labs. NASPGHAN

19. Lactulose/others if encephalopathy occurs
    Purpose: Treat high ammonia.
    How: Traps ammonia in gut.
    Side effects: Diarrhea, bloating. NASPGHAN

20. Pain/itch adjuncts (gabapentin under specialist care in refractory cases)
    Purpose: Central itch modulation.
    How: Neuromodulation pathways.
    Side effects: Sedation, dizziness. PFIC

---

Dietary “molecular” supplements

1. Vitamin E (TPGS/tocophersolan) — 15–25 IU/kg/day.
   Function: Neuroprotection, RBC membrane stability.
   Mechanism: Water-soluble vitamin E absorbs without bile. Gastro Journal+1

2. Vitamin D3 (cholecalciferol) or calcitriol — dose per levels; high doses often needed in cholestasis.
   Function: Bone mineralization.
   Mechanism: Restores 25-OH D and calcium handling. AASLD+1

3. Vitamin A (retinol) — supervised dosing.
   Function: Vision, immunity, growth.
   Mechanism: Replaces malabsorbed vitamin. AASLD

4. Vitamin K (phytonadione) — per INR and levels.
   Function: Clotting factor activation.
   Mechanism: Fixes γ-carboxylation deficit. NCBI

5. MCT oil — add spoonfuls to feeds as advised.
   Function: Extra calories.
   Mechanism: Medium-chain fats absorb directly via portal vein without bile. Orpha

6. Essential fatty acids (linoleic/α-linolenic, DHA) — diet or supplements.
   Function: Prevent EFAD, support neural/retinal health.
   Mechanism: Replaces unmet essential lipid needs. NASPGHAN

7. Zinc — ~1 mg/kg/day elemental when low.
   Function: Growth, immunity, wound healing.
   Mechanism: Corrects deficiency common in chronic cholestasis. NASPGHAN

8. Calcium — per age/weight along with vitamin D.
   Function: Bone strength.
   Mechanism: Supports mineralization. NASPGHAN

9. Phosphate — if low.
   Function: Bone and energy metabolism.
   Mechanism: Replaces deficit. NASPGHAN

10. Water-miscible multivitamin (A, D, E, K formulations).
    Function: Broad micronutrient coverage.
    Mechanism: Improved absorption in cholestasis. NASPGHAN

---

Regenerative / stem-cell” drugs

There are no approved “immunity-booster,” regenerative, or stem-cell drugs for ALGS. The therapies below are research-stage or procedural and should only be accessed in clinical trials or specialized centers.

1. AAV-based JAG1 gene therapy (experimental).
   Concept: Deliver functional JAG1 to target tissues. Dose: None established. Mechanism: Restore Notch signaling. Status: Preclinical/early translational; not approved. PMC

2. Genome/base-editing approaches to JAG1/NOTCH2 (experimental).
   Concept: Correct pathogenic variants in vivo or ex vivo. Dose: None established. Mechanism: Fix causal mutation. Status: Research only. PMC

3. iPSC-derived hepatocyte therapy (cell therapy, experimental).
   Concept: Replace dysfunctional hepatocytes. Dose: Procedural. Mechanism: Improve bile handling. Status: Investigational. NCBI

4. Mesenchymal stromal cell infusions (experimental).
   Concept: Anti-inflammatory/antifibrotic paracrine effects. Dose: Investigational protocols only. Mechanism: Modulate fibrosis/inflammation. Status: Not approved. PMC

5. Hepatocyte transplantation (bridge therapy, procedural).
   Concept: Infuse donor hepatocytes to bridge to transplant. Dose: Procedure-based. Mechanism: Partial metabolic support. Status: Limited/experimental for ALGS. NCBI

6. FXR/FGF19-pathway modulators (various agents, research).
   Concept: Alter bile acid synthesis/signaling. Dose: Trial-specific. Mechanism: Reduce bile acid load; mixed effects on itch. Status: Not standard in ALGS. PFIC

---

Surgeries / procedures

1. Partial External Biliary Diversion (PEBD).
   What: Surgical conduit that diverts part of bile outside the body.
   Why: For intractable itch/xanthomas when medicines fail and before transplant.
   Evidence: Many children get marked itch relief and improved lipids/growth. PubMed+1

2. Ileal exclusion / internal diversion options.
   What: Surgical bypass of terminal ileum or internal bile diversion.
   Why: To reduce enterohepatic bile acid cycling and itch.
   Evidence: Options vary by center; selected cases benefit. ScienceDirect

3. Liver transplantation.
   What: Replace diseased liver.
   Why: End-stage liver disease, refractory pruritus, growth failure, or complications (e.g., portal hypertension). Post-transplant survival is high in expert centers. NCBI

4. Cardiac interventions (catheter or surgery).
   What: Treat pulmonary artery stenosis or congenital defects (e.g., TOF).
   Why: Improve oxygenation and heart function. NCBI

5. Endoscopic variceal ligation (EVL) / banding (procedure).
   What: Endoscopic control of esophageal varices.
   Why: Prevent or treat GI bleeding in portal hypertension. NCBI

Important caution: Kasai portoenterostomy is for biliary atresia and is not recommended for ALGS; when performed due to misdiagnosis, outcomes are worse. Early genetic/clinical evaluation helps avoid unnecessary Kasai. PubMed+2PMC+2

---

Preventions

1. Early evaluation for prolonged jaundice (>2 weeks in infants). Detect cholestasis promptly. NASPGHAN

2. Vaccinate fully, plus HAV/HBV if not immune. Protect the liver. NCBI

3. Avoid hepatotoxic drugs/alcohol (age-appropriate counseling). Reduce extra liver stress. NCBI

4. Use water-miscible vitamins A, D, E, K with lab monitoring. Prevent deficiency. NASPGHAN

5. Nutrition with MCT and adequate protein/energy. Prevent growth failure. Orpha

6. Skin-itch care routine to prevent scratching infections. Protect skin. AASLD

7. Bone protection: vitamin D/calcium, safe activity, fall prevention. AASLD

8. Regular heart, kidney, and eye checks. Catch treatable problems. NCBI

9. HCC surveillance (US + AFP every 6 months) when advised. Early tumor detection. NCBI

10. Family genetic counseling. Understand recurrence risk and options. NCBI

---

When to see doctors (red flags)

• Worsening jaundice, pale stools, dark urine, severe itch, or poor growth.

• Any bleeding, easy bruising, or very high INR concerns.

• Abdominal swelling, vomiting blood, or black stools.

• Severe fatigue, confusion, fever, or signs of infection (possible cholangitis).

• New headaches, weakness, speech problems (possible vascular events).

• Chest pain, fainting, blue lips, breathing difficulty (cardiac).

• Bone pain or fractures with minimal trauma.

• Before any surgery, anesthesia, or new medication (to check liver safety). NCBI

---

What to eat and what to avoid

Eat / add:

1. Energy-dense meals every 2–3 hours (nut butters, avocado, eggs).

2. MCT-enriched formulas/oils per dietitian.

3. Lean proteins (fish, poultry, legumes) to support growth.

4. Fruits/vegetables for fiber and micronutrients.

5. Water-miscible A, D, E, K supplements as prescribed.

Limit / avoid:

1. Very fatty, fried foods if they worsen steatorrhea.
2. Grapefruit or new herbal products without checking interactions.
3. Excess added sugars that displace protein/healthy fats.
4. Alcohol (adolescents/adults) and smoking/vaping (vascular risk).
5. Raw shellfish (infection risk to the liver). Orpha

---

Frequently asked questions

1. Is ALGS curable?
   No. It is lifelong, but many symptoms can be controlled. Some people need liver transplant. NCBI

2. What gene causes ALGS?
   Usually JAG1, rarely NOTCH2. Both affect Notch signaling. NCBI

3. How is ALGS diagnosed?
   By clinical features (bile duct paucity + other signs) and/or genetic testing. NCBI

4. Why is the itch so bad?
   Bile acids and other mediators build up and irritate nerves. AASLD

5. What medicines help the itch?
   Start with cholestyramine; add rifampin, naltrexone, sertraline; now IBAT inhibitors (maralixibat, odevixibat) are approved for ALGS pruritus. AASLD+2FDA Access Data+2

6. Are maralixibat or odevixibat safe for kids?
   Yes, both have FDA indications in ALGS with pediatric dosing; monitoring of LFTs and vitamins is required. FDA Access Data+1

7. Will UDCA cure ALGS?
   No, but it can improve bile flow and some lab values. NASPGHAN

8. Do all patients need surgery?
   No. Some respond to medicines and vitamins; surgery is for severe or non-responsive cases. NCBI

9. What is PEBD?
   A bile diversion surgery that can reduce itch and improve xanthomas/growth in selected patients. PubMed

10. Is Kasai surgery used in ALGS?
    No. It is for biliary atresia. In ALGS it can worsen outcomes if done by mistake. PubMed

11. Can ALGS affect the heart or brain vessels?
    Yes. Pulmonary artery stenosis and other vascular issues can occur; surveillance is important. NCBI

12. Is there a cancer risk?
    There is an increased risk of hepatocellular carcinoma, so many patients get US + AFP every 6 months. NCBI

13. Can adults have ALGS with mild symptoms?
    Yes. Expression is highly variable; some adults have subtle features. NCBI

14. What about vitamins?
    Use water-miscible forms and monitor levels to avoid deficiency or toxicity. TPGS vitamin E is often needed. NASPGHAN+1

15. Is gene therapy available now?
    Not yet. It’s being researched. Standard care focuses on symptom control and preventing complications. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 11, 2025.